SIGY Archives - BioTuesdays

Markets

Sigyn announces reverse split to support uplist to Nasdaq

Sigyn Therapeutics (OTCQB:SIGY) announced a 1-for-40 reverse split. Sigyn’s common stock is expected to begin trading on a split-adjusted basis on OTCQB when the market opens on Jan. 31. As a result of the split...

January 30, 2024

Developments

Sigyn outlines 2023 achievements, 2024 outlook

In a letter to shareholders to Sigyn Therapeutics’ (OTCQB:SIGY) shareholders, Jim Joyce, chairman and CEO, said as a small organization operating in a world with short-term expectations, the company has “not wavered...

January 8, 2024

Executive Moves

Sigyn Therapeutics names Jerry DeCiccio as CFO

Sigyn Therapeutics (OTCQB:SIGY) appointed Jerry DeCiccio as CFO, succeeding Jeremy Farrell, who was appointed CFO in March of 2022. Mr. DeCiccio has more than 40 years of financial industry experience, previously...

December 12, 2023

Developments

Sigyn Therapeutics submits international patent application for ChemoPrep and ChemoPure

Sigyn Therapeutics (OTCQB:SIGY) submitted a Patent Cooperation Treaty (PCT) application for the technologies it is developing to enhance the clinical benefit of chemotherapeutic drugs. Chemotherapy is the most commonly...

October 5, 2023

Developments

CytoSorbents appears to validate Sigyn’s therapeutic strategy

CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...

November 10, 2022

Developments

Sigyn Therapeutics to register ChemoPrep and ChemoPure as trademarks for devices to enhance cancer therapy

Sigyn Therapeutics (OTCQB:SIGY) disclosed that trademark applications to register ChemoPrep and ChemoPure have been filed with the United States Patent and Trademark Office (USPTO). The intent-to-use trademark...

October 13, 2022

Developments

Sigyn Therapeutics files U.S. patent entitled “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”

Sigyn Therapeutics (OTCQB:SIGY) filed a provisional patent application entitled, “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity,” with the United States Patent and Trademark Office. Cancer is...

October 6, 2022

Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...

October 4, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Developments

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Sigyn Therapeutics (OTCQB:SIGY) plans to pursue first-in-human feasibility studies of its Sigyn Therapy in end-stage renal disease (ESRD) patients suffering from excess inflammation and/or endotoxemia. Sigyn Therapy is...

September 14, 2022

Tag - SIGY

Sigyn announces reverse split to support uplist to Nasdaq

Sigyn outlines 2023 achievements, 2024 outlook

Sigyn Therapeutics names Jerry DeCiccio as CFO

Sigyn Therapeutics submits international patent application for ChemoPrep and ChemoPure

CytoSorbents appears to validate Sigyn’s therapeutic strategy

Sigyn Therapeutics to register ChemoPrep and ChemoPure as trademarks for devices to enhance cancer therapy

Sigyn Therapeutics files U.S. patent entitled “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

General

More